← Back to Search

Diuretic

Diuretics for Early Chronic Kidney Disease (DOCK Trial)

Phase 4
Recruiting
Led By Lucile P Gregg, MD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
The presence of CKD stages 1, 2, or 3, as defined below by Kidney Disease Improving Global Outcomes guidelines, for a period of at least 3 months.
Male or female Veterans age 18 years or older. There will be no upper age limit.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks
Awards & highlights

DOCK Trial Summary

This trial will study whether treating early kidney disease with diuretics can improve long-term cardiovascular outcomes.

Who is the study for?
This trial is for Veterans with early-stage chronic kidney disease (CKD stages 1-3) who have high blood pressure. Participants must be at least 18 years old, able to give informed consent, and not on dialysis or a recipient of a kidney transplant. Those with severe heart issues, liver cirrhosis, major limb amputation, pregnancy, or certain devices like pacemakers are excluded.Check my eligibility
What is being tested?
The study tests whether diuretics (like hydrochlorothiazide or furosemide) can reduce fluid overload in the body and improve cardiovascular health in people with early CKD. It compares two methods of measuring fluid overload and observes changes in symptoms and short-term heart function after treatment.See study design
What are the potential side effects?
Diuretics may cause dehydration, electrolyte imbalances (like low potassium), dizziness upon standing up due to lowered blood pressure, increased urination frequency, fatigue, muscle cramps or weakness.

DOCK Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with mild to moderate kidney disease for at least 3 months.
Select...
I am a Veteran aged 18 or older.

DOCK Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in NT-pro-BNP
Secondary outcome measures
Change in BNP
Change in FACIT-F score
Change in KDQOL
+8 more

DOCK Trial Design

1Treatment groups
Experimental Treatment
Group I: Diuretic augmentationExperimental Treatment1 Intervention
The participant's blood pressure medication regimen will be altered to initiate a thiazide-type or loop diuretic in those not already prescribed a diuretic, or to increase the dose if one is already prescribed.

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,609 Previous Clinical Trials
3,306,557 Total Patients Enrolled
Lucile P Gregg, MDPrincipal InvestigatorMichael E. DeBakey VA Medical Center, Houston, TX
1 Previous Clinical Trials

Media Library

Diuretic Augmentation (Diuretic) Clinical Trial Eligibility Overview. Trial Name: NCT05171686 — Phase 4
Chronic Kidney Disease Research Study Groups: Diuretic augmentation

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are the researchers expecting to recruit for this experiment?

"At this time, the trial is no longer enrolling patients. It was initially posted on February 1st 2023 and last modified on November 16th 2022. For those still searching for a suitable study, there are presently 1211 clinical trials focused on hypertension and 31 studies involving Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide or bumetanide) that are actively recruiting participants."

Answered by AI

Are individuals eligible to join this experiment presently?

"Unfortunately, this medical trial is no longer actively seeking participants. The original posting was on February 1st 2023 and the most recent update came November 16th 2022. However, if you are looking for additional studies there are 1211 trials recruiting patients with hypertension and 31 which require augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide or bumetanide)."

Answered by AI

Is the FDA sanctioning Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide) as a viable treatment?

"The efficacy and safety of diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide or bumetanide) have been adequately demonstrated in clinical trials; thus receiving a score of 3."

Answered by AI

To which conditions is diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide) generally prescribed?

"Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide or bumetanide) is a common approach to treating edema and serves as an intervention for cerebrovascular accident, antihypertensive agents and kidney diseases."

Answered by AI

What other research projects have examined the effectiveness of diuretic augmentation involving hydrochlorothiazide, chlorthalidone, furosemide, torsemide or bumetanide?

"Currently, 31 medical trials are underway to analyse the effectiveness of Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide). 11 of these studies have reached Phase 3. While Halifax has several sites conducting this research, there is a total 132 clinical trial locations across North America researching Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide)."

Answered by AI

Who else is applying?

What state do they live in?
Texas
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
What site did they apply to?
Michael E. DeBakey VA Medical Center, Houston, TX
Recent research and studies
clinicaltrials.govStudy
Diuretics and Volume Overload in Early CKD
2023. "Diuretics and Volume Overload in Early CKD". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05171686.
All > Chronic Kidney Disease > High Blood Pressure
~22 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top